March 18, 2020 / 10:45 AM / 14 days ago

BRIEF-Sage Therapeutics Announces Development Plan For Zuranolone Following Meeting With The FDA

March 18 (Reuters) - SAGE Therapeutics Inc:

* SAGE THERAPEUTICS ANNOUNCES DEVELOPMENT PLAN FOR ZURANOLONE (SAGE-217) FOLLOWING BREAKTHROUGH THERAPY GUIDANCE MEETING WITH THE U.S. FOOD & DRUG ADMINISTRATION

* SAGE THERAPEUTICS - EXPECTED REGULATORY PATHWAY FOR EPISODIC TREATMENT OF MAJOR DEPRESSION REMAINS UNCHANGED WITH PLAN FOR ONE NEW EFFICACY STUDY

* SAGE THERAPEUTICS INC - PURSUING TWO ADDITIONAL PATHWAYS WITH GOAL OF ACCELERATING PATIENT ACCESS TO ZURANOLONE

* SAGE THERAPEUTICS INC - FILING PATHWAY FOR POSTPARTUM DEPRESSION ANTICIPATED TO REQUIRE ONE ADDITIONAL STUDY WITHOUT LONG-TERM FOLLOW-UP

* SAGE THERAPEUTICS -PLAN TO PURSUE NOVEL DEVELOPMENT FOR ACUTE, RAPID TREATMENT OF MAJOR DEPRESSIVE EPISODES WHEN CO-INITIATED WITH NEW ANTIDEPRESSANT

* SAGE THERAPEUTICS INC - ANTICIPATES ITS BALANCE OF CASH, CASH EQUIVALENTS, AMONG OTHERS WILL SUPPORT OPERATIONS INTO 2022

* SAGE THERAPEUTICS INC - RE-ASSESSING ITS RESOURCE ALLOCATION AND PRIORITIZATION STRATEGY IN LIGHT OF DEVELOPMENT OF ZURANOLONE

* SAGE THERAPEUTICS INC - PLANS TO SHARE ITS UPDATED RESOURCE ALLOCATION STRATEGY DURING ITS Q1 EARNINGS CALL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below